multiple myeloma

News

Is GSK’s Blenrep heading for a renaissance?

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the

News

Abecma delay gives Carvykti a chance to catch up

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f

R&D

The longitudinal history of medicines innovation: Part two

As we move forward in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines

R&D

The longitudinal history of medicines innovation: Part One

As we move forwards in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines

News

Leschly steps down as 2seventy wields the axe

2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also

News

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least

Is GSK’s Blenrep heading for a renaissance?

Abecma delay gives Carvykti a chance to catch up

The longitudinal history of medicines innovation: Part two

The longitudinal history of medicines innovation: Part One

Leschly steps down as 2seventy wields the axe

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

multiple myeloma

Editor's Picks